logo
All You Need to Know About EPR Properties (EPR) Rating Upgrade to Buy

All You Need to Know About EPR Properties (EPR) Rating Upgrade to Buy

Yahoo26-05-2025

EPR Properties (EPR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for EPR Properties basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for EPR Properties imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
This real estate investment trust is expected to earn $5.04 per share for the fiscal year ending December 2025, which represents a year-over-year change of 4.1%.
Analysts have been steadily raising their estimates for EPR Properties. Over the past three months, the Zacks Consensus Estimate for the company has increased 1.8%.
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of EPR Properties to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EPR Properties (EPR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month

Yahoo

time22 minutes ago

  • Yahoo

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month

CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

You can still score the PlayStation DualSense Edge controller at its best-ever price
You can still score the PlayStation DualSense Edge controller at its best-ever price

Yahoo

time24 minutes ago

  • Yahoo

You can still score the PlayStation DualSense Edge controller at its best-ever price

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. SAVE $30.99: As of June 6, the PlayStation DualSense Edge Wireless Controller is on sale for $169 at Amazon. That's 15% off its list price of $199.99 and its lowest price yet. Opens in a new window Credit: PlayStation PlayStation DualSense Edge Wireless Controller $169 at Amazon $199.99 Save $30.99 Get Deal PlayStation's Days of Play is still going strong, as are the many great PlayStation deals available right now. If you've been looking to pick up a new controller for your PS5, or an extra for your next co-op session, the PlayStation DualSense Edge Controller is still down to its lowest-ever price at Amazon. The PlayStation DualSense Edge Controller has received a 15% discount at Amazon that has dropped its price from $199.99 to $169. The deal applies to both the midnight black and white versions of the controller as well, so you can scoop up the one that best matches your PS5 setup. SEE ALSO: Get the PlayStation 5 Pro for its lowest-ever price at Target The DualSense Edge has plenty to offer PS5 players, with stick caps you can change out, adjustable triggers, mappable back buttons, and more to help you personalize how you play. The Days of Play sale runs runs through June 11, so act fast to save on the PlayStation DualSense Edge Controller. If you're looking for the standard DualSense controllers instead, those are also on sale right now. Roku Ultra 4K Ultimate Streaming Player (2024 Release) — $79.99 (List Price $99.99) Beats Pill Bluetooth Speaker — $99.95 (List Price $149.95) Roborock Qrevo Master Robot Vacuum and Mop — $899.99 (List Price $1599.99) Apple AirTag (4-Pack) — $74.99 (List Price $99.00) DualSense Edge Wireless Controller — $169.00 (List Price $199.99)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store